SCHEMBL20186950

SCHEMBL20186950

C=CC(=O)Nc1cccc(C)c1Nc1ncnc2c(C(=O)Nc3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)csc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMX P51813 6/20 0.61
BLK P51451 2/20 0.52
EGFR P00533 1/20 0.52
ERBB2 P04626 1/20 0.52
TEC P42680 1/20 0.52
TXK P42681 1/20 0.52
JAK3 P52333 1/20 0.52
BTK Q06187 1/20 0.52
ERBB4 Q15303 1/20 0.52
BRAF P15056 11/20 0.51
ABL1 P00519 1/20 0.49
SRC P12931 1/20 0.49
DDR1 Q08345 1/20 0.49
MAPK14 Q16539 1/20 0.49
DDR2 Q16832 1/20 0.49
CSF1R P07333 2/20 0.49
KIT P10721 1/20 0.49
RAF1 P04049 1/20 0.48
PDGFRB P09619 1/20 0.48
PDGFRA P16234 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2311108 0.86 BRAF (0.60) BMXBTKBRAFABL1SRC
SCHEMBL12433876 0.85 BRAF (0.60) BMXBRAFABL1SRCDDR1
SCHEMBL2312901 0.85 BRAF (0.63) BRAFABL1SRCDDR1MAPK14
SCHEMBL2315865 0.84 BRAF (0.57) BMXBTKBRAFABL1SRC
SCHEMBL2318954 0.84 BRAF (0.63) BMXBRAFABL1SRCDDR1
SCHEMBL12433873 0.82 BTK (0.58) BTKBRAFABL1SRCMAPK14
SCHEMBL2313222 0.82 CSF1R (0.66) BTKBRAFABL1SRCDDR1
SCHEMBL20186910 0.81 BMX (0.49) BMXEGFRBTKDDR1MAPK14
SCHEMBL12433877 0.81 BRAF (0.55) BTKBRAFABL1SRCMAPK14
SCHEMBL20186911 0.80 FGFR4 (0.42) EGFRBTKBRAFSRCDDR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10040803-B2 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-08-07 US claimed
US-20180148459-A1 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-05-31 US claimed
US-10040803-B2 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-08-07 US disclosed
US-10040803-B2 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-08-07 US disclosed
US-20180148459-A1 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-05-31 US disclosed
US-20180148459-A1 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148459-A1 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS CDK2, CDK2AP2, CDK2AP1 BMX 472/4885BLK 439/4885EGFR 722/4885
US-10040803-B2 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors CDK2, CDK2AP2, CDK2AP1 BMX 472/4885BLK 439/4885EGFR 722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.